CRTAC1

CRTAC1 is a secreted, multi-domain glycoprotein that functions as an extracellular matrix component in cartilage and as a context-dependent signaling regulator in multiple tissues. Its crystal structure reveals a compact β-propeller–TTR fold stabilized by calcium, potassium, and sodium ions, where potassium binding between β-propeller blades is essential for structural integrity and concealment of reactive free cysteines (PMID:39029889). CRTAC1 is secreted by chondrocytes into cartilage ECM in a BMP4-stimulated manner and contains FG-GAP repeats and an RGD integrin-binding motif (PMID:17074475); in tumor cells, it suppresses proliferation, migration, and EMT by inhibiting integrin/FAK signaling, downregulating YY1 to inactivate TGF-β, and enhancing cisplatin sensitivity through RyR-mediated Ca²⁺ release that activates NFAT–STUB1-dependent Akt1 degradation (PMID:41708954, PMID:34818994, PMID:37633993). In osteoarthritis, senescent synoviocyte-derived CRTAC1 binds NRF2 in chondrocytes to suppress SIRT3 transcription, causing mitochondrial dysfunction and cartilage degradation (PMID:41311393).

1. 2001 Medium

   Establishing CRTAC1 as a novel chondrocyte-specific gene resolved the question of whether a molecular marker could distinguish chondrocytes from osteoblasts and mesenchymal stem cells, and identified its EGF-like calcium-binding domain.

   Evidence Gene cloning, sequence analysis, and cell-type-specific expression profiling in human chondrocyte/osteoblast/MSC cultures

   PMID:11139377

   Open questions at the time

   • No functional assay performed
   • Expression restricted to cultured cells without in vivo tissue validation
2. 2006 High

   Demonstrating that CRTAC1-A is secreted into cartilage ECM under BMP4 stimulation, and mapping its O-glycosylation and FG-GAP/RGD domain architecture, established CRTAC1 as a bona fide ECM glycoprotein with potential integrin-binding function.

   Evidence Deletion mutagenesis, O-glycosylation inhibitor assays, immunolocalization in articular cartilage, BMP4 stimulation in chondrocyte cultures

   PMID:17074475

   Open questions at the time

   • No direct integrin binding demonstrated
   • Functional consequence of O-glycosylation unknown
3. 2010 Low

   Computational prediction of CRTAC1's N-terminal seven-bladed β-propeller fold related to integrin α-chains provided the first structural framework, later confirmed crystallographically.

   Evidence Structural prediction and phylogenetic analysis across deeply divergent organisms

   PMID:20171266

   Open questions at the time

   • Purely computational — awaited experimental structural validation
   • No functional implications tested
4. 2021 Medium

   Revealing that CRTAC1 co-immunoprecipitates with YY1 and transcriptionally downregulates it to inactivate TGF-β signaling established the first intracellular signaling mechanism by which CRTAC1 suppresses tumor cell proliferation and EMT.

   Evidence Co-IP, immunofluorescence co-localization, ChIP, luciferase reporter, and functional overexpression/knockdown assays in bladder cancer cells

   PMID:34818994

   Open questions at the time

   • CRTAC1–YY1 interaction domain not mapped
   • Unclear how a secreted protein physically interacts with a nuclear transcription factor
   • Single cancer type tested
5. 2022 Medium

   Identifying DNMT3A-mediated promoter methylation as the mechanism of CRTAC1 silencing in bladder cancer explained how CRTAC1 tumor-suppressive function is epigenetically lost, linking lncRNA TPRG1-AS1/TFAP2A to CRTAC1 suppression.

   Evidence ChIP-qPCR, luciferase reporters, DNA methylation analysis, rescue experiments in bladder urothelial carcinoma cells

   PMID:36410635

   Open questions at the time

   • Methylation-mediated silencing not validated in patient cohorts with matched expression data
   • Whether this epigenetic mechanism operates in other cancer types is unknown
6. 2023 Medium

   Demonstrating that CRTAC1 enhances cisplatin sensitivity through RyR-mediated Ca²⁺ release → NFAT activation → STUB1 induction → Akt1 degradation provided a detailed signaling cascade linking CRTAC1 to chemotherapy response in NSCLC.

   Evidence Overexpression/knockdown, calcium imaging, NFAT reporter assays, Western blot, and in vivo mouse tumor xenograft experiments

   PMID:37633993

   Open questions at the time

   • Direct molecular target of CRTAC1 that triggers RyR-mediated Ca²⁺ release not identified
   • Mechanism not reconstituted with purified components
7. 2024 High

   The 1.6 Å crystal structure resolved CRTAC1's three-domain architecture (β-propeller–TTR) and revealed that potassium ions are critical structural cofactors, answering long-standing questions about its fold and ion dependence.

   Evidence X-ray crystallography, ion-dependent stability assays, tryptophan fluorescence, Cys→Ser mutagenesis

   PMID:39029889

   Open questions at the time

   • No ligand or receptor co-crystal structure
   • Functional significance of the TTR domain remains undefined
   • Whether potassium-dependent conformational changes regulate signaling is untested
8. 2024 Medium

   Single-cell analysis of spinal ligament degeneration identified CRTAC1+ chondrocyte-like cells as targets of SPP1+ macrophage signaling via ATF3, positioning CRTAC1 within an intercellular calcification axis.

   Evidence Single-cell RNA-seq, SCENIC TF analysis, CellChat, and experimental ATF3 validation

   PMID:39158018

   Open questions at the time

   • CRTAC1's causal role in calcification not tested by loss-of-function
   • ATF3 direct binding to CRTAC1 promoter not confirmed by ChIP
9. 2025 Medium

   Demonstrating that senescent FLS-derived CRTAC1 binds NRF2 in chondrocytes to suppress SIRT3 transcription, causing FOXO3a acetylation and mitochondrial dysfunction, provided a paracrine mechanism for CRTAC1 in osteoarthritis cartilage degradation.

   Evidence Co-IP for CRTAC1–NRF2 binding, SIRT3 transcription and FOXO3a acetylation assays, mitophagy assays, in vivo AAV-SIRT3 rescue in mouse OA model, single-cell sequencing

   PMID:41311393

   Open questions at the time

   • CRTAC1–NRF2 binding domain and stoichiometry unmapped
   • Whether intracellular CRTAC1–NRF2 interaction requires receptor-mediated uptake or an intracellular isoform is unclear
10. 2026 Medium

    Showing that CRTAC1 suppresses lung adenocarcinoma via integrin/FAK pathway inhibition provided the first direct evidence that its RGD-containing domain functionally engages integrin signaling to exert tumor-suppressive effects.

    Evidence In vitro and in vivo tumor models with knockdown/overexpression, Western blot for integrin/FAK markers

    PMID:41708954

    Open questions at the time

    • Specific integrin heterodimer bound by CRTAC1 not identified
    • No direct binding assay between CRTAC1 and integrin/FAK

• A central unresolved question is how a secreted ECM glycoprotein mechanistically engages intracellular signaling partners (YY1, NRF2) — whether through receptor-mediated internalization, an intracellular isoform, or another mechanism — and what the physiological ligand or receptor for CRTAC1's β-propeller domain is.
• No cell-surface receptor for CRTAC1 identified
• No structural basis for CRTAC1–integrin or CRTAC1–NRF2 interaction
• Knockout mouse phenotype not reported